Oncolytic viruses and histone deacetylase inhibitors—A multi-pronged strategy to target tumor cells

Abstract Oncolytic viruses (OVs) have shown promise as cancer therapeutics in pre-clinical and clinical testing; however, it is unlikely that OVs will constitute a stand-alone treatment. Histone deacetylase inhibitors (HDIs) represent a class of anticancer agents known to influence epigenetic modifi...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine & growth factor reviews 2010-04, Vol.21 (2), p.153-159
Main Authors: Nguyen, Thi Lien-Anh, Wilson, Marnie Goodwin, Hiscott, John
Format: Article
Language:English
Subjects:
Advanced Basic Science
Antitumor agents
Combination therapy
Histone deacetylase inhibitors
Innate immune response
Interferons
Oncolytic virus
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Oncolytic viruses (OVs) have shown promise as cancer therapeutics in pre-clinical and clinical testing; however, it is unlikely that OVs will constitute a stand-alone treatment. Histone deacetylase inhibitors (HDIs) represent a class of anticancer agents known to influence epigenetic modifications of chromatin, alter gene expression and manipulate a variety of signaling pathways, in some cases blunting the cellular antiviral response. Recent studies have shown that combining OV therapy with HDI treatment enhances viral replication and synergistically induces the killing of cancer cells in vitro and in vivo , an effect that has now been demonstrated in variety of virus/HDI combinations. This review discusses the results obtained with the different OV/HDI combinations, the rationale supporting these combinations and the advantages for oncolytic virus therapy.
ISSN:1359-6101
DOI:10.1016/j.cytogfr.2010.03.002